Newsletter Tool

PM Tracker

Today’s Big News

Mar 11, 2025

A once-yearly PrEP? Gilead’s lenacapavir shows promise as company plots phase 3

NIH grants powered $94B in economic activity in 2024 and supported more than 400,000 jobs: report

Illumina aims to cut $100M in costs following China import ban

Merck opens $1B Gardasil manufacturing facility in North Carolina

Pfizer, Arvinas post mixed breast cancer survival results in first phase 3

Featured

A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3

By Angus Liu

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart—only once a year.

NIH grants powered $94B in economic activity in 2024 and supported more than 400K jobs: report

By Darren Incorvaia

Funding granted to researchers by the National Institutes of Health powered $94.58 billion in economic activity across the U.S. in 2024, according to an annual report published March 11 by biomedical research advocacy organization United for Medical Research. The number was a $1.68 billion increase from the prior year.

Merck opens $1B Gardasil manufacturing facility in North Carolina

By Kevin Dunleavy

At its sprawling manufacturing complex in Durham, N.C., Merck has opened a new $1 billion plant slated to produce megablockbuster HPV vaccine Gardasil.

Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader

By James Waldron

Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has a path to regulators.

Illumina aims to cut $100M in costs following China import ban

By Conor Hale

Illumina also lowered its annual financial forecast, as it plans to deal with a loss of revenue from China after the country's retaliation for U.S. tariffs.

As Humira succession plan played out, AbbVie's Rob Michael collected $18.5M in his first year as CEO

By Fraiser Kansteiner

For his work in 2024, AbbVie helmsman Robert Michael—who took over the CEO post from Richard Gonzalez on July 1—collected roughly $18.5 million in total pay. The figure was a $4 million jump over the sum he earned in 2023, when he was the Chicago drugmaker's chief operating officer.

Coherus to lose 30% of staff as part of Udenyca sale to Accord

By James Waldron

Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma.

Siemens Healthineers expands photon-counting CT family with new FDA clearances

By Conor Hale

Siemens Healthineers aims to bring photon-counting technology to single-source CT scanners aimed at ERs and other facilities.

Daiichi taps Nosis to deliver RNA therapies beyond the liver

By Nick Paul Taylor

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver.

With AbbVie in its sights, Tenpoint names commercial chief ahead of vision drug launch

By Nick Paul Taylor

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly appointed chief commercial officer, Kearney will oversee preparations to launch a rival to AbbVie’s age-related blurry near vision product Vuity.

Fierce podcasts

Don’t miss an episode

'The Top Line': A look at biotech's biggest money raisers of 2024

This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape.

'The Top Line': Research reveals ‘ticking DNA clock’ behind Huntington’s disease

Podnosis: What’s next for digital health investing in 2025?

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper